Kersten Dirk 4

What Happened Dirk Kersten (Director) reported two open-market sales of Dyne Therapeutics (DYN) stock. On 2026-04-17 he (via the reporting entity) sold 211,974 shares for a weighted average price of $20.29 ($4,301,292). On 2026-04-20 he sold 125,274 shares for a weighted average price of $20.07 ($2,513,898). Total proceeds reported: $6,815,190. These were sales (not purchases), and the filing indicates the trades were executed under a pre-established 10b5-1 trading plan.

Key Details

• Transaction dates and amounts:
  • 2026-04-17: 211,974 shares sold, weighted avg price $20.29, proceeds $4,301,292 (footnote: prices across $20.00–$20.75).
  • 2026-04-20: 125,274 shares sold, weighted avg price $20.07, proceeds $2,513,898.
• Total shares sold: 337,248; total proceeds: $6,815,190.
• The filing was submitted on 2026-04-21 (within the normal Form 4 reporting window), so it is not marked late.
• Ownership/structure notes from the filing:
  • The shares sold are held directly by ForDyne B.V., an entity jointly owned by Forbion funds. The filing explains complex institutional ownership and that Kersten is a partner/committee member of the Forbion entities; he disclaims direct beneficial ownership except to the extent of any pecuniary interest.
• Weighted-average prices / ranges: the filing includes weighted-average prices and footnotes offering to provide a per-price breakdown on request.
• No "shares owned after transaction" total was provided in the excerpt you supplied.

Context

• The transactions were executed pursuant to a Rule 10b5-1 trading plan (adopted Nov 11, 2025), which means the sales were preplanned and are commonly treated as routine rather than a real-time signal of insider sentiment.
• These sales were of shares held by an institutional entity (ForDyne/Forbion-related), not necessarily direct personal stock sales; the filing’s footnotes describe delegation of voting/dispositive powers and disclaimers of beneficial ownership.